Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT01286012
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 108 participants
- Registry
-
NCT01286012
-
- Other papers using this trial's data
- Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01286012. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2014-03-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
- Acronym
- PRIME
- Condition
- End Stage Renal Disease
- Intervention (Drug)
- Soluble Ferric Pyrophosphate in liquid bicarbonate
- Intervention (Drug)
- Placebo: Conventional liquid bicarbonate
- Intervention (Drug)
- Erythrocyte Stimulating Agent (ESA)
- Intervention (Drug)
- Intravenous (IV) Iron
- Lead sponsor
- Rockwell Medical Technologies, Inc.
Record details
- Record id
cardio:ct-nct01286012- Content hash
76bc461b3e37b408a1373fabd0f1091c68e620e63be0ec0215988cc7f1e8ffd5